Literature DB >> 12709557

Severe Parkinson's disease in rheumatoid arthritis patient treated with infliximab.

P Hrycaj, I Korczowska, J K Łacki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12709557     DOI： 10.1093/rheumatology/keg160

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  5 in total

Review 1.  Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Authors:  K L Hyrich; A J Silman; K D Watson; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2004-07-08       Impact factor: 19.103

2.  Parkinsonism as a side effect of infliximab.

Authors:  Jakob Nørgaard Henriksen; Bengt Oluf Mikael Eriksson
Journal:  BMJ Case Rep       Date:  2016-05-05

3.  Genome-wide association study confirms extant PD risk loci among the Dutch.

Authors:  Javier Simón-Sánchez; Jacobus J van Hilten; Bart van de Warrenburg; Bart Post; Henk W Berendse; Sampath Arepalli; Dena G Hernandez; Rob M A de Bie; Daan Velseboer; Hans Scheffer; Bas Bloem; Karin D van Dijk; Fernando Rivadeneira; Albert Hofman; André G Uitterlinden; Patrizia Rizzu; Zoltan Bochdanovits; Andrew B Singleton; Peter Heutink
Journal:  Eur J Hum Genet       Date:  2011-01-19       Impact factor: 4.246

Review 4.  Movement and Other Neurodegenerative Syndromes in Patients with Systemic Rheumatic Diseases: A Case Series of 8 Patients and Review of the Literature.

Authors:  Rikitha Menezes; Alexander Pantelyat; Izlem Izbudak; Julius Birnbaum
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.889

5.  Loss of Parkin reduces inflammatory arthritis by inhibiting p53 degradation.

Authors:  Yu Yeon Jung; Dong Ju Son; Hye Lim Lee; Dae Hwan Kim; Min Jong Song; Young Wan Ham; Youngsoo Kim; Sang Bae Han; Mi Hee Park; Jin Tae Hong
Journal:  Redox Biol       Date:  2017-04-05       Impact factor: 11.799
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.